{"contentid": 488094, "importid": NaN, "name": "Sanofi gives notice it is termination deal with Oxford Biomedica", "introduction": "UK-based Oxford Biomedica, a gene and cell therapy group, announced today that French pharma major Sanofi has given notice that it intends to terminate the collaboration and license agreement for process development and manufacturing of lentiviral vectors to treat hemophilia.", "content": "<p>UK-based Oxford Biomedica (LSE: OXB), a gene and cell therapy group, announced today that French pharma major Sanofi (Euronext: SAN) has given notice that it intends to terminate the collaboration and license agreement for process development and manufacturing of lentiviral vectors to treat hemophilia.</p>\n<p>News of the decision, made via a notification to the London Stock Exchange, pushed the UK firm&rsquo;s shares down almost 6% to 961.95 pence by mid-afternoon trading today.</p>\n<p>Oxford Biomedica had originally signed the $100 million collaboration and license agreement with Bioverativ, which was acquired by Sanofi in February 2018 in an $11.6 billion deal.</p>\n<p>The company expects that the impact on revenue will be negligible over the coming 24-month period.</p>\n<p>The termination follows last June&rsquo;s decision by Sanofi to drop its alliance with Oxford Biomedica on two ophthalmic programs - SAR422459 for Stargardt disease and SAR421869 for Usher&rsquo;s Syndrome type 1b.</p>", "date": "2021-03-19 14:21:00", "meta_title": "Sanofi gives notice it is termination deal with Oxford Biomedica", "meta_keywords": "Oxford Biomedica, Sanofi, License, Agreement, Termination, Lentiviral vectors, Hemophilia", "meta_description": "Sanofi gives notice it is termination deal with Oxford Biomedica", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-19 14:20:29", "updated": "2021-03-19 14:29:36", "access": NaN, "url": "https://www.thepharmaletter.com/article/sanofi-gives-notice-it-is-termination-deal-with-oxford-biomedica", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "oxford_biomedica_company.jpg", "image2id": "oxford_biomedica_small-1-.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology", "topic_tag": "Deals, Licensing", "geography_tag": "France, UK", "company_tag": "BIOVERATIV INC., Oxford BioMedica, Sanofi", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-19 14:21:00"}